Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD

IF 9.4 1区医学 Q1 UROLOGY & NEPHROLOGY

American Journal of Kidney Diseases Pub Date : 2025-04-29 DOI:10.1053/j.ajkd.2025.03.016

Yen-Chieh Lee MD PhD, Li-Chiu Wu MS, Vin-Cent Wu MD PhD, Chia-Hsuin Chang MD ScD

引用次数: 0

Abstract

Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular, kidney, and survival outcomes in patients with type 2 diabetes; however, the comparative effectiveness of these drugs in a real-world setting remains unclear.

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂和钠/葡萄糖共转运蛋白2抑制剂在预防2型糖尿病和CKD患者慢性肾衰竭和死亡率中的比较效果

胰高血糖素样肽-1受体激动剂（GLP-1RAs）和钠/葡萄糖共转运蛋白2 （SGLT2）抑制剂可改善2型糖尿病患者的心血管、肾脏和生存结局；然而，这些药物在现实环境中的相对有效性仍不清楚。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Kidney Diseases 医学-泌尿学与肾脏学

CiteScore

20.40

自引率

2.30%

发文量

732

审稿时长

3-8 weeks

期刊介绍： The American Journal of Kidney Diseases (AJKD), the National Kidney Foundation's official journal, is globally recognized for its leadership in clinical nephrology content. Monthly, AJKD publishes original investigations on kidney diseases, hypertension, dialysis therapies, and kidney transplantation. Rigorous peer-review, statistical scrutiny, and a structured format characterize the publication process. Each issue includes case reports unveiling new diseases and potential therapeutic strategies.